Plain-English translation of ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a newer medication, combined with lenalidomide to see if it can replace the traditional approach of chemotherapy followed by a stem cell transplant in treating newly diagnosed multiple myeloma. The study will also compare alone to standard medications during the long-term maintenance phase of treatment, which lasts about 2 years.
Multiple myeloma is a blood cancer that has traditionally been treated with intensive chemotherapy and stem cell transplant, which can be difficult for patients to tolerate. This trial is exploring whether the new treatment can achieve similar or better results with potentially fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will first receive 4 months of standard chemotherapy (D-VRd) as induction therapy. Then you will be randomly assigned to either receive the new medication combination ( and lenalidomide) or to undergo stem cell transplant followed by standard chemotherapy—both as consolidation therapy. After consolidation, you will be re-assigned to either continue with standard maintenance medications or alone for approximately 2 years. Throughout the study, you will have regular clinic visits, blood draws, and imaging scans to monitor your response to treatment.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
Belgium